NICE approves liraglutide for diabetic patients not achieving glucose controlBMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c5062 (Published 15 September 2010) Cite this as: BMJ 2010;341:c5062
- Susan Mayor
Treatment with the incretin mimetic liraglutide can be considered as part of dual therapy—in combination with metformin or a sulphonylurea—in patients with type 2 diabetes failing to achieve blood glucose control and who are intolerant to currently available drugs, recommends final draft guidance from the National Institute for Health and Clinical Excellence.
An earlier draft of the appraisal had recommended against the use of liraglutide as part of dual therapy, but NICE has reviewed its decision on the basis of further data, particularly on cost effectiveness.
NICE’s appraisal also finds that liraglutide is clinically and cost effective as part of triple therapy in patients with a body mass index (BMI) of 35 or over. In these …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial